172 related articles for article (PubMed ID: 24709886)
21. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS
Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196
[TBL] [Abstract][Full Text] [Related]
22. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
23. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
25. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Wilson TR; Fridlyand J; Yan Y; Penuel E; Burton L; Chan E; Peng J; Lin E; Wang Y; Sosman J; Ribas A; Li J; Moffat J; Sutherlin DP; Koeppen H; Merchant M; Neve R; Settleman J
Nature; 2012 Jul; 487(7408):505-9. PubMed ID: 22763448
[TBL] [Abstract][Full Text] [Related]
26. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N
Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.
Wong DJ; Robert L; Atefi MS; Lassen A; Avarappatt G; Cerniglia M; Avramis E; Tsoi J; Foulad D; Graeber TG; Comin-Anduix B; Samatar A; Lo RS; Ribas A
Mol Cancer; 2014 Aug; 13():194. PubMed ID: 25142146
[TBL] [Abstract][Full Text] [Related]
29. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
30. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA
Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.
Hartsough EJ; Basile KJ; Aplin AE
Mol Cancer Res; 2014 May; 12(5):795-802. PubMed ID: 24520098
[TBL] [Abstract][Full Text] [Related]
32. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
33. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.
Kugel CH; Hartsough EJ; Davies MA; Setiady YY; Aplin AE
Cancer Res; 2014 Aug; 74(15):4122-32. PubMed ID: 25035390
[TBL] [Abstract][Full Text] [Related]
34. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.
Jalili A; Mertz KD; Romanov J; Wagner C; Kalthoff F; Stuetz A; Pathria G; Gschaider M; Stingl G; Wagner SN
PLoS One; 2013; 8(7):e69064. PubMed ID: 23935925
[TBL] [Abstract][Full Text] [Related]
35. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
36. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.
Gross A; Niemetz-Rahn A; Nonnenmacher A; Tucholski J; Keilholz U; Fusi A
Target Oncol; 2015 Mar; 10(1):77-84. PubMed ID: 24824730
[TBL] [Abstract][Full Text] [Related]
37. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
[TBL] [Abstract][Full Text] [Related]
38. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA
Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344
[TBL] [Abstract][Full Text] [Related]
39. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
[TBL] [Abstract][Full Text] [Related]
40. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]